Radiopharm Theranostics RADX
NASDAQ RADX
$0.88 -0.07 (-7.70%)
At close: Nov 9, 2026 · 4:00 PM EST

Radiopharm Theranostics (RADX) Current Deferred Revenue (2024 - 2026)

Updated

Radiopharm Theranostics (RADX) recorded Current Deferred Revenue of $5,720 in fiscal Q4 2026 (quarter ended Jun 30, 2026), down 48.1% from $11,019 a year earlier.

Analysis

Radiopharm Theranostics (RADX) Current Deferred Revenue (2024 - 2026) Analysis & Trends

At the end of FY2026 (ended Jun 30, 2026), Radiopharm Theranostics reported Current Deferred Revenue of $5,477, down 99.7% from FY2025.

  • Across earlier fiscal years, Current Deferred Revenue came in at $1.72 million in FY2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,261.99 Bn 1,235.61 Bn 20.46 Bn
2 Johnson & Johnson 678.93 Bn 598.79 Bn 17.30 Bn
3 AbbVie 518.29 Bn 486.30 Bn 13.12 Bn
4 Merck 365.98 Bn 328.92 Bn 13.19 Bn
5 Novartis Ag 316.85 Bn 290.09 Bn -
6 Astrazeneca 293.40 Bn 267.29 Bn 13.26 Bn
7 Amgen 251.78 Bn 203.43 Bn 7.58 Bn
8 Gilead Sciences 210.61 Bn 185.71 Bn 6.73 Bn
9 Pfizer 166.87 Bn 114.23 Bn 12.56 Bn
10 Radiopharm Theranostics 2.70 Bn 2.62 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 806,410.00
Jun 30, 2025 1.72 Mn
Dec 31, 2024 3.16 Mn
API Access

Radiopharm Theranostics Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=RADX&period=max&api_key=YOUR_API_KEY